Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


BET Bromodomain Inhibition Suppresses Human T Cell Function.

Georgiev P, Wang Y, Muise ES, Bandi ML, Blumenschein W, Sathe M, Pinheiro EM, Shumway SD.

Immunohorizons. 2019 Jul 11;3(7):294-305. doi: 10.4049/immunohorizons.1900037.


Identification of Kinases Responsible for p53-Dependent Autophagy.

Celano SL, Yco LP, Kortus MG, Solitro AR, Gunaydin H, Scott M, Spooner E, O'Hagan RC, Fuller P, Martin KR, Shumway SD, MacKeigan JP.

iScience. 2019 May 31;15:109-118. doi: 10.1016/j.isci.2019.04.023. Epub 2019 Apr 23.


A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress.

Martin KR, Celano SL, Solitro AR, Gunaydin H, Scott M, O'Hagan RC, Shumway SD, Fuller P, MacKeigan JP.

iScience. 2018 Oct 26;8:74-84. doi: 10.1016/j.isci.2018.09.012. Epub 2018 Sep 19.


MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Bridges KA, Chen X, Liu H, Rock C, Buchholz TA, Shumway SD, Skinner HD, Meyn RE.

Oncotarget. 2016 Nov 1;7(44):71660-71672. doi: 10.18632/oncotarget.12311.


An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies.

O'Neil J, Benita Y, Feldman I, Chenard M, Roberts B, Liu Y, Li J, Kral A, Lejnine S, Loboda A, Arthur W, Cristescu R, Haines BB, Winter C, Zhang T, Bloecher A, Shumway SD.

Mol Cancer Ther. 2016 Jun;15(6):1155-62. doi: 10.1158/1535-7163.MCT-15-0843. Epub 2016 Mar 16.


The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.

Pokorny JL, Calligaris D, Gupta SK, Iyekegbe DO Jr, Mueller D, Bakken KK, Carlson BL, Schroeder MA, Evans DL, Lou Z, Decker PA, Eckel-Passow JE, Pucci V, Ma B, Shumway SD, Elmquist WF, Agar NY, Sarkaria JN.

Clin Cancer Res. 2015 Apr 15;21(8):1916-24. doi: 10.1158/1078-0432.CCR-14-2588. Epub 2015 Jan 21.


Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.

Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C, Zawel L, Fawell SE, Gilliland DG, Shumway SD.

Mol Cancer Ther. 2013 Aug;12(8):1442-52. doi: 10.1158/1535-7163.MCT-13-0025. Epub 2013 May 22.


Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition.

Guertin AD, Martin MM, Roberts B, Hurd M, Qu X, Miselis NR, Liu Y, Li J, Feldman I, Benita Y, Bloecher A, Toniatti C, Shumway SD.

Cancer Cell Int. 2012 Nov 13;12(1):45. doi: 10.1186/1475-2867-12-45.


Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.

Russell MR, Levin K, Rader J, Belcastro L, Li Y, Martinez D, Pawel B, Shumway SD, Maris JM, Cole KA.

Cancer Res. 2013 Jan 15;73(2):776-84. doi: 10.1158/0008-5472.CAN-12-2669. Epub 2012 Nov 7.


Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC.

Cancer Discov. 2012 Jun;2(6):524-39. doi: 10.1158/2159-8290.CD-11-0320. Epub 2012 Apr 23.


Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.

Sarcar B, Kahali S, Prabhu AH, Shumway SD, Xu Y, Demuth T, Chinnaiyan P.

Mol Cancer Ther. 2011 Dec;10(12):2405-14. doi: 10.1158/1535-7163.MCT-11-0469. Epub 2011 Oct 12.


MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M.

Clin Cancer Res. 2011 May 1;17(9):2799-806. doi: 10.1158/1078-0432.CCR-10-2580. Epub 2011 Mar 9.


Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.

Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, Lutterbach BA, Chi A, Paweletz C, Allison T, Yan Y, Munshi SK, Klippel A, Kraus M, Bobkova EV, Deshmukh S, Xu Z, Mueller U, Szewczak AA, Pan BS, Richon V, Pollock R, Blume-Jensen P, Northrup A, Andersen JN.

J Biol Chem. 2011 Feb 25;286(8):6433-48. doi: 10.1074/jbc.M110.156463. Epub 2010 Nov 30.


Twice primed: cyclin E is phosphorylated and isomerized before being ubiquitinated.

Shumway SD, Xiong Y.

Mol Cell. 2006 Jul 21;23(2):149-50. Review.


Negative regulation of TSC1-TSC2 by mammalian D-type cyclins.

Zacharek SJ, Xiong Y, Shumway SD.

Cancer Res. 2005 Dec 15;65(24):11354-60.


Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases.

Goldenberg SJ, Cascio TC, Shumway SD, Garbutt KC, Liu J, Xiong Y, Zheng N.

Cell. 2004 Nov 12;119(4):517-28.


Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells.

O'Connor S, Shumway SD, Amanna IJ, Hayes CE, Miyamoto S.

Mol Cell Biol. 2004 Jun;24(11):4895-908.


Evidence for unique calmodulin-dependent nuclear factor-kappaB regulation in WEHI-231 B cells.

Shumway SD, Berchtold CM, Gould MN, Miyamoto S.

Mol Pharmacol. 2002 Jan;61(1):177-85.


NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events.

Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, Boothman DA, Miyamoto S.

J Biol Chem. 2000 Mar 31;275(13):9501-9.


The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain.

Shumway SD, Maki M, Miyamoto S.

J Biol Chem. 1999 Oct 22;274(43):30874-81.


Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells.

Miyamoto S, Seufzer BJ, Shumway SD.

Mol Cell Biol. 1998 Jan;18(1):19-29.

Supplemental Content

Loading ...
Support Center